Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression
about
Molecular mechanisms of superoxide production by complex III: a bacterial versus human mitochondrial comparative case studyThe interplay between drug resistance and fitness in malaria parasitesIn Vitro Resistance Selections for Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered GrowthStructural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug actionReconstructing the Qo site of Plasmodium falciparum bc 1 complex in the yeast enzymeUnderstanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methodsThe Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent MechanismParasites resistant to the antimalarial atovaquone fail to transmit by mosquitoesA Novel Methodology for Bioenergetic Analysis of Plasmodium falciparum Reveals a Glucose-Regulated Metabolic Shift and Enables Mode of Action Analyses of Mitochondrial Inhibitors.Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reportsNovel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in NigeriaAntimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1Antimalarial pharmacology and therapeutics of atovaquoneSaccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.Within-Host Selection of Drug Resistance in a Mouse Model of Repeated Incomplete Malaria Treatment: Comparison between Atovaquone and Pyrimethamine.Antitubercular pharmacodynamics of phenothiazinesStructural basis of resistance to anti-cytochrome bc₁ complex inhibitors: implication for drug improvementCurrent therapies and future possibilities for drug development against liver-stage malaria.Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.Selection for chloroquine-sensitive Plasmodium falciparum by wild Anopheles arabiensis in Southern Zambia.In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitorsNovel inhibitors of the Plasmodium falciparum electron transport chain.Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potentialTargeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era.A novel live-dead staining methodology to study malaria parasite viability.Exploring the Molecular Basis of Qo bc1 Complex Inhibitors Activity to Find Novel Antimalarials Hits.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.Synthesis, SAR, and Docking Studies Disclose 2-Arylfuran-1,4-naphthoquinones as In Vitro Antiplasmodial Hits.Selection of cytochrome B mutants by putative PfNDH2 inhibitors
P2860
Q26825065-1D824906-BDE2-4050-A678-F5CA84BBBBC4Q26998596-F44B561C-1295-4F8D-9AA9-F7EFF926BA44Q27683596-CCE5E17A-6178-4ABA-BB2C-CA522E9BCEC4Q27690642-7C69D7C9-48D2-475C-9665-54B6C8DDE71AQ28535248-4B5752CF-4522-4007-BD62-DAC775B8630EQ28543795-E73D9321-CF42-4E3D-9265-E0C778C82E54Q28547465-F70E6BFD-637B-46E8-8337-4DEC5295A776Q30380109-18E9E2FC-5CDD-47C6-AC15-2E592DCD3ABAQ33920004-8898F923-683A-4B51-9CF8-FD05260DE7EDQ34058304-2F85AEF1-8896-4A4B-9356-6D61C11DCF12Q34802106-9F7986DA-C93E-4366-86BE-E3107FE5AC3BQ35031417-42C1B7AB-1829-4F36-B510-2295BC87FC90Q35131253-738A9A7A-4B95-4CEF-877C-6E825F1A2AF8Q35745986-D6A98A64-7B78-46E0-BD87-E71A9792678AQ35822252-672B06A2-9CB9-48AF-AA26-B478ED8D7188Q36675149-51089DAB-5B7D-4049-AD76-62DB67294CE0Q36677835-2F49C0CF-DF61-42F5-899B-530D48EEC232Q36951722-30A9A2DE-619A-4EB7-B274-26B607C09208Q37120173-37940BBB-26EA-485E-937A-AB567DE85AF3Q37425838-E70B04A3-9EE9-4249-84C9-5E40B23BE4EBQ37611650-0291656E-95E5-47F7-A6B1-EF60551A711AQ38176703-5B726242-7CDA-4F42-923F-471FAEBFCDF5Q38294829-28B0F67E-089B-4CF9-890D-9FD9D9CF01E8Q39306287-AC515251-B97F-495F-ACC4-4E7830EEEA85Q39341007-E4B71428-054D-4DAD-92DC-E39AD16705E4Q39535134-489B92CC-0FC9-4891-A036-157B207AE495Q40106428-B8C35AF6-7EA4-4293-93B0-4CF25E67F215Q41547525-8F572F04-D394-4DAB-9D90-EF6D7CA42A84Q43102405-DE7E64B6-A3E2-4472-A032-9D2060BD0588Q47098538-324AB72F-ED0A-41E5-96D0-E30C7C243A6EQ56378245-B69B2ACF-6BD3-4AC4-96E1-09EC0DDF75EF
P2860
Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cytochrome b mutation Y268S co ...... urnover and protein expression
@ast
Cytochrome b mutation Y268S co ...... urnover and protein expression
@en
type
label
Cytochrome b mutation Y268S co ...... urnover and protein expression
@ast
Cytochrome b mutation Y268S co ...... urnover and protein expression
@en
prefLabel
Cytochrome b mutation Y268S co ...... urnover and protein expression
@ast
Cytochrome b mutation Y268S co ...... urnover and protein expression
@en
P2093
P2860
P50
P356
P1476
Cytochrome b mutation Y268S co ...... urnover and protein expression
@en
P2093
Alexandre S Lawrenson
Ashley J Warman
David J Johnson
Mohammed Al-Helal
Nicholas Fisher
Paul M O'Neill
Roslaini Abd Majid
Thomas Antoine
P2860
P304
P356
10.1074/JBC.M111.324319
P407
P577
2012-01-26T00:00:00Z